user

GEMCITABINE-DOCETAXEL VERSUS CISPLATIN-GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER

被引：0
|
作者：
Al-Gizawy, S. M. [1 ]
Mostafa, H. G. [1 ]
机构：
[1] Assiut Univ, Dept Clin Oncol, Fac Med, Assiut, Egypt
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/j.ejca.2014.03.065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P0021
引用
收藏
页码：E15 / E15
页数：1
相关论文
共 50 条
  • [21] Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Sujith Kalmadi
    Giles McNeill
    Mellar Davis
    David Peereboom
    David Adelstein
    Tarek Mekhail
    Medical Oncology, 2006, 23 : 507 - 513
  • [22] Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Kalmadi, Sujith
    McNeill, Giles
    Davis, Mellar
    Peereboom, David
    Adelstein, David
    Mekhail, Tarek
    MEDICAL ONCOLOGY, 2006, 23 (04) : 507 - 513
  • [23] Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
    Wilbur, H. Catherine
    Durham, Jennifer N.
    Lim, Su Jin
    Purtell, Katrina
    Bever, Katherine M.
    Laheru, Daniel A.
    De Jesus-Acosta, Ana
    Azad, Nilofer S.
    Wilt, Bradley
    Diaz, Luis A.
    Le, Dung T.
    Wang, Hao
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1672 - 1677
  • [24] Docetaxel in combination with Gemcitabine as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Barata, Fernando
    Sousa, Amelia
    Camacho, Elvira
    Costa, Marco S.
    Canario, Dolores
    Nogueira, Fernando
    Semedo, Eulalia
    ANNALS OF ONCOLOGY, 2004, 15 : 179 - 179
  • [25] BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Benekli, Mustafa
    Gunaydin, Yusuf
    Inanc, Mevlude
    Ozkan, Metin
    Demirci, Ayse
    Demirci, Umut
    Suner, Ali
    Karaca, Halit
    Tonyali, Onder
    Berk, Veli
    Buyukberber, Suleyman
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S563 - S563
  • [26] Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
    Reck, Martin
    IMMUNOTHERAPY, 2018, 10 (02) : 93 - 105
  • [27] Sequential cisplatin-gemcitabine-docetaxel vs docetaxel-gemcitabine in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Interim results of an ongoing phase II trial.
    Binder, D
    Beinert, T
    Schweisfurth, H
    Grah, C
    Temmesfeld-Wollbrock, B
    Müller-Hagen, G
    Schäper, C
    Schürmann, D
    Suttorp, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 644S - 644S
  • [28] Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial
    Georgoulias, V
    Samonis, G
    Papadakis, E
    Alexopoulos, A
    Tsiafaki, X
    Rapti, A
    Veslemes, M
    Grigoratou, T
    Palamidas, P
    Kourossis, C
    Mavroudis, D
    Kakolyris, S
    Giannakakis, T
    Vlachonikolis, J
    LUNG CANCER, 2001, 34 : S47 - S51
  • [29] Combination of docetaxel and gemcitabine effective in non-small-cell lung cancer
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 186 - 186
  • [30] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    Thatcher, Nick
    Hirsch, Fred R.
    Luft, Alexander V.
    Szczesna, Aleksandro
    Ciuleanu, Tudor E.
    Dediu, Mircea
    Ramlau, Rodryg
    Galiulin, Rinat K.
    Balint, Beatrix
    Losonczy, Gyoergy
    Kazarnowicz, Andrzej
    Park, Keunchil
    Schumann, Christian
    Reck, Martin
    Depenbrock, Henrik
    Nanda, Shivani
    Letunic, Anamarija Kruljac
    Kurek, Raffacl
    Paz-Ares, Luis
    Socinskf, Mark A.
    LANCET ONCOLOGY, 2015, 16 (07): : 763 - 774
12345